- Trials with a EudraCT protocol (118)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (2)
118 result(s) found for: Capsule Endoscopy.
Displaying page 1 of 6.
EudraCT Number: 2005-004423-19 | Sponsor Protocol Number: CF/01 | Start Date*: 2005-12-06 |
Sponsor Name:The North West London Hospitals NHS Trust, Northwick Park Hospital | ||
Full Title: A randomised study of the optimal bowel preparation for routine Capsule endoscopy using Citramag and Senna or Metoclopramide. | ||
Medical condition: Investigation of suspected small bowel disease by Capsule Endoscopy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2012-005754-38 | Sponsor Protocol Number: AOC-PSM-201301 | Start Date*: 2013-07-10 |
Sponsor Name:HOSPITAL DE GALDAKAO-USANSOLO | ||
Full Title: Title : COMPARISON OF THE EFFECTIVENESS OF TWO PROTOCOLS FOR BOWEL CLEANING FOR CAPSULE ENDOSCOPY STUDIO | ||
Medical condition: We do not use these products in a concrete disease. We compare the effectiveness of these products to obtain an accurate bowel cleansing before performing a capsule endoscopic study. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2013-003187-31 | Sponsor Protocol Number: GN09CA403 | Start Date*: 2015-03-19 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:NHS Greater Glasgow & Clyde | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Misoprostol for the Healing of Small Bowel Ulceration in Patients with Obscure Blood Loss while Taking Low-Dose Aspirin or Non-Steroidal Anti-inflammatory Drugs [MASTERS Trial] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Small bowel ulcers associated with iron deficiency anaemia or obscure blood loss in patients using aspirin or non-steroidal anti-inflammatory drugs | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: GB (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-002579-33 | Sponsor Protocol Number: EE-301 | Start Date*: 2020-03-26 | |||||||||||
Sponsor Name:Phathom Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Two-Phase, Multicenter Study to Evaluate the Efficacy and Safety of Vonoprazan 20 mg Compared to Lansoprazole 30 mg for Healing in Patients with Erosive Esophag... | |||||||||||||
Medical condition: Erosive Esophagitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) CZ (Completed) HU (Completed) PL (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022382-10 | Sponsor Protocol Number: CCX114151 | Start Date*: 2011-01-06 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
Full Title: A Randomised, Double-blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects with Moderately-to Severely Active Crohn’s Disease | |||||||||||||
Medical condition: Subjects with Moderately-to-Severely Active Crohn’s Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) NL (Completed) CZ (Completed) SE (Prematurely Ended) NO (Completed) BE (Completed) DK (Completed) HU (Completed) IT (Completed) SK (Completed) AT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000319-41 | Sponsor Protocol Number: RPC01-3101 | Start Date*: 2015-09-18 | |||||||||||
Sponsor Name:Celgene International II Sàrl (CIS II) | |||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Oral RPC1063 as Induction and Maintenance Therapy for Moderate to Severe Ulcerative Colitis | |||||||||||||
Medical condition: ulcerative colitis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) SK (Completed) HU (Completed) CZ (Completed) NL (Completed) GB (Completed) BE (Completed) BG (Completed) PL (Completed) HR (Completed) LV (Completed) AT (Completed) GR (Completed) ES (Prematurely Ended) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-012935-13 | Sponsor Protocol Number: D9120C00019 | Start Date*: 2009-12-03 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A randomized, double-blind, placebo controlled, multi-centre phase IIb dose finding study to assess the effect on GERD symptoms, safety and tolerability during four weeks treatment with AZD3355 in ... | |||||||||||||
Medical condition: Gastroesophageal Reflux Disease (GERD) is the intended indication. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) LV (Completed) HU (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004292-31 | Sponsor Protocol Number: RPC01-3201 | Start Date*: 2018-05-21 | |||||||||||
Sponsor Name:Celgene International II Sàrl | |||||||||||||
Full Title: Induction Study #1 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn’s Disease | |||||||||||||
Medical condition: Moderately to Severely Active Crohn’s Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Completed) CZ (Completed) DE (Completed) BG (Ongoing) ES (Ongoing) NO (Ongoing) BE (Completed) DK (Completed) PL (Ongoing) IE (Completed) GB (GB - no longer in EU/EEA) HR (Ongoing) FR (Completed) IT (Ongoing) RO (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004293-33 | Sponsor Protocol Number: RPC01-3202 | Start Date*: 2018-03-06 | |||||||||||
Sponsor Name:Celgene International II Sàrl | |||||||||||||
Full Title: Induction Study #2 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn’s Disease | |||||||||||||
Medical condition: Moderately to Severely Active Crohn’s Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) SK (Completed) LT (Completed) DE (Completed) FR (Completed) SI (Completed) AT (Completed) BG (Completed) GR (Completed) ES (Ongoing) SE (Completed) NL (Completed) PL (Completed) PT (Completed) FI (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000518-31 | Sponsor Protocol Number: LYC-30937-2001 | Start Date*: 2016-08-16 | |||||||||||
Sponsor Name:Lycera Corp. | |||||||||||||
Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF INDUCTION THERAPY WITH LYC-30937-EC IN SUBJECTS WITH ACTIVE ULCERATIVE COLITIS | |||||||||||||
Medical condition: Ulcerative Colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) HU (Completed) PL (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-002308-11 | Sponsor Protocol Number: IM047-001 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Celgene International II Sàrl | |||||||||||||
Full Title: A phase 2/3, multicenter, randomized, double-blind study to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of oral ozanimod (RPC1063) in pediatric subjects with moderately to ... | |||||||||||||
Medical condition: Moderately to Severely Active Ulcerative Colitis | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-003123-38 | Sponsor Protocol Number: RPC01-202 | Start Date*: 2012-12-11 | |||||||||||
Sponsor Name:Celgene International II Sàrl (CIS II) | |||||||||||||
Full Title: A PHASE 2, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PARALLEL-GROUP STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF INDUCTION THERAPY WITH RPC1063 IN PATIENTS WITH MODERATELY... | |||||||||||||
Medical condition: Moderately to severely active Ulcerative Colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) HU (Completed) PL (Completed) SK (Completed) BG (Completed) GR (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001893-32 | Sponsor Protocol Number: GLPG1205-CL-211 | Start Date*: 2015-01-19 | |||||||||||
Sponsor Name:Galapagos NV | |||||||||||||
Full Title: Phase II, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of GLPG1205 in Patients with Moderate to Severe U... | |||||||||||||
Medical condition: Ulcerative Colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) HU (Completed) BE (Completed) DE (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001942-28 | Sponsor Protocol Number: APD334-003 | Start Date*: 2015-12-10 | |||||||||||
Sponsor Name:Arena Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study to Investigate the Safety and Efficacy of APD334 in Patients with Moderately to Severely Active Ulcerativ... | |||||||||||||
Medical condition: Ulcerative colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) GB (Completed) ES (Completed) DE (Completed) LV (Completed) HU (Completed) LT (Completed) FR (Completed) PL (Completed) BG (Completed) BE (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-001317-42 | Sponsor Protocol Number: SAG-43/SBE | Start Date*: 2008-07-09 |
Sponsor Name:Prof. Dr. Istvan Racz | ||
Full Title: Open label, uncontrolled pilot study on the effect of mucosal healing with 3 g mesalazine granules in NSAID induced small bowel enteropathy, evaluated by video capsule endoscopy after 4 weeks of tr... | ||
Medical condition: treatment of NSAID induced small bowel enteropathy | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: HU (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-001976-48 | Sponsor Protocol Number: IM011023 | Start Date*: 2018-08-23 | ||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | ||||||||||||||||||
Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects with Moderate to Severe Crohn's Disease | ||||||||||||||||||
Medical condition: Crohn's Disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) HU (Ongoing) FR (Ongoing) ES (Ongoing) PL (Completed) DE (Completed) DK (Prematurely Ended) PT (Completed) NL (Completed) BE (Completed) IT (Ongoing) RO (Ongoing) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-003974-18 | Sponsor Protocol Number: VB-201-064 | Start Date*: 2012-12-10 | |||||||||||
Sponsor Name:Vascular Biogenics Ltd. | |||||||||||||
Full Title: A Randomized, Double-Blind, 12-Week, Placebo-Controlled Study Followed by a 12-Week Extension Phase Without Placebo to Evaluate the Efficacy and Safety of Oral VB-201 in Subjects with Mild to Moder... | |||||||||||||
Medical condition: Mild to Moderate Ulcerative Colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004507-73 | Sponsor Protocol Number: TAK-390MR_205 | Start Date*: 2016-02-26 | |||||||||||
Sponsor Name:Takeda Development Centre Europe Ltd. | |||||||||||||
Full Title: A Phase 2, Double Blind, Up to 40 Week, Multicenter Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Es... | |||||||||||||
Medical condition: Erosive Esophagitis in paediatric subjects aged 1 to 11 years | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Temporarily Halted) PT (Temporarily Halted) BE (Ongoing) PL (Trial now transitioned) LT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-005166-12 | Sponsor Protocol Number: HMPL-004-US-02 | Start Date*: 2008-07-29 | |||||||||||
Sponsor Name:Hutchison MediPharma Enterprises Limited | |||||||||||||
Full Title: A Phase II, Randomized, Multi-Centre, Double-Blind, Placebo-Controlled Trial of HMPL-004 in Patients with Mild to Moderate Active Ulcerative Colitis with or without Mesalamine | |||||||||||||
Medical condition: active mild to moderate ulcerative colitis defined as a Mayo clinical score of 4-10 points | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-006656-14 | Sponsor Protocol Number: MH002-PC-201 | Start Date*: 2022-06-22 | |||||||||||
Sponsor Name:MRM Health NV | |||||||||||||
Full Title: Exploratory Study to Evaluate Safety, Mechanistic and Clinical Effects of MH002 in Subjects with Acute Pouchitis | |||||||||||||
Medical condition: Acute Pouchitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.